Venmax Drugs Reports Highest Profit After Tax in Five Quarters Amid Mixed Financial Performance
Venmax Drugs & Pharmaceuticals announced its financial results for the quarter ending March 2025, revealing the highest Profit After Tax in five quarters at Rs 0.78 crore and an Earnings per Share peak of Rs 1.49. However, concerns arise from high Non-Operating Income relative to Profit Before Tax.
Venmax Drugs & Pharmaceuticals has recently reported its financial results for the quarter ending March 2025, with the announcement made on May 9, 2025. The company, operating within the Pharmaceuticals & Drugs industry, has experienced notable evaluation changes in its financial metrics over the past three months.The financial results indicate that Venmax Drugs achieved its highest Profit After Tax (PAT) in the last five quarters, reaching Rs 0.78 crore. This positive trend in PAT suggests a strengthening in the company's profitability. Additionally, the Earnings per Share (EPS) also reached a peak of Rs 1.49 during the same period, reflecting an increase in earnings for shareholders.
However, the financial landscape is not without its challenges. The company reported that its Non-Operating Income constituted 132.47% of its Profit Before Tax (PBT), raising concerns about the sustainability of its business model, as reliance on non-business activities can pose risks to long-term financial health.
Overall, Venmax Drugs has undergone a revision in its score, reflecting the mixed performance in its financial results.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
